AU2015367531B2 - Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARbeta) agonists - Google Patents
Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARbeta) agonists Download PDFInfo
- Publication number
- AU2015367531B2 AU2015367531B2 AU2015367531A AU2015367531A AU2015367531B2 AU 2015367531 B2 AU2015367531 B2 AU 2015367531B2 AU 2015367531 A AU2015367531 A AU 2015367531A AU 2015367531 A AU2015367531 A AU 2015367531A AU 2015367531 B2 AU2015367531 B2 AU 2015367531B2
- Authority
- AU
- Australia
- Prior art keywords
- neuropathy
- bhba
- injury
- compound according
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *c1ccc(*)c(*)c1 Chemical compound *c1ccc(*)c(*)c1 0.000 description 14
- TZSUTFHSOCFQQI-UHFFFAOYSA-N CCOC(c1nc(c(C)ccc2C)c2[o]1)=O Chemical compound CCOC(c1nc(c(C)ccc2C)c2[o]1)=O TZSUTFHSOCFQQI-UHFFFAOYSA-N 0.000 description 2
- JGKJUMWLTZYPPE-UHFFFAOYSA-N Cc1cc(OC)c(C)cc1O Chemical compound Cc1cc(OC)c(C)cc1O JGKJUMWLTZYPPE-UHFFFAOYSA-N 0.000 description 2
- FZVHWAYAYYCFIN-UHFFFAOYSA-N Cc1ccc(C)c2c1cc(-c1nc(-c3ccc(C(O)=O)c(F)c3)n[s]1)[o]2 Chemical compound Cc1ccc(C)c2c1cc(-c1nc(-c3ccc(C(O)=O)c(F)c3)n[s]1)[o]2 FZVHWAYAYYCFIN-UHFFFAOYSA-N 0.000 description 2
- SEPONMOEDNBVNA-UHFFFAOYSA-N CC(C)(C)OC(c1ccc(-c2nc(-c3cc4c(C)ccc(C)c4[o]3)n[o]2)c(F)c1)=O Chemical compound CC(C)(C)OC(c1ccc(-c2nc(-c3cc4c(C)ccc(C)c4[o]3)n[o]2)c(F)c1)=O SEPONMOEDNBVNA-UHFFFAOYSA-N 0.000 description 1
- SYBVOJDCTDHDBN-UHFFFAOYSA-N CC(C)(C)OC(c1ccc(C(O)=O)c(F)c1)=O Chemical compound CC(C)(C)OC(c1ccc(C(O)=O)c(F)c1)=O SYBVOJDCTDHDBN-UHFFFAOYSA-N 0.000 description 1
- SCTOGLSBDNJHLZ-UHFFFAOYSA-N CC(C)c1c(cc(-c2nc(-c(cc3)ccc3C(C)=C)n[o]2)[o]2)c2c(C)cc1 Chemical compound CC(C)c1c(cc(-c2nc(-c(cc3)ccc3C(C)=C)n[o]2)[o]2)c2c(C)cc1 SCTOGLSBDNJHLZ-UHFFFAOYSA-N 0.000 description 1
- HDPWRCPQDSMYDP-UHFFFAOYSA-N CC(c(cc1)ccc1-c1n[s]c(-c2cc3c(C)ccc(C)c3[o]2)n1)=C Chemical compound CC(c(cc1)ccc1-c1n[s]c(-c2cc3c(C)ccc(C)c3[o]2)n1)=C HDPWRCPQDSMYDP-UHFFFAOYSA-N 0.000 description 1
- PSNFSIKMPDJCQF-UHFFFAOYSA-N CC(c1ccc(-c2n[o]c(-c3cc(c(C)ccc4C)c4[o]3)n2)c(N)c1)=C Chemical compound CC(c1ccc(-c2n[o]c(-c3cc(c(C)ccc4C)c4[o]3)n2)c(N)c1)=C PSNFSIKMPDJCQF-UHFFFAOYSA-N 0.000 description 1
- MAGKBOIMWPQTOP-UHFFFAOYSA-N CCOC(CBr)[O](CC)I Chemical compound CCOC(CBr)[O](CC)I MAGKBOIMWPQTOP-UHFFFAOYSA-N 0.000 description 1
- XUYOBJMVGYEDOF-UHFFFAOYSA-N CCOC(c1ccc(B2OC(C)(C)C(C)(C)O2)cc1)=C Chemical compound CCOC(c1ccc(B2OC(C)(C)C(C)(C)O2)cc1)=C XUYOBJMVGYEDOF-UHFFFAOYSA-N 0.000 description 1
- XSXSSXYWUFLLEB-UHFFFAOYSA-N CNOC(c1cc(c(Cl)ccc2Cl)c2[o]1)=N Chemical compound CNOC(c1cc(c(Cl)ccc2Cl)c2[o]1)=N XSXSSXYWUFLLEB-UHFFFAOYSA-N 0.000 description 1
- PJAUWJBJFGOLTN-UHFFFAOYSA-N COC(c(cc1)cc([N+]([O-])=O)c1/C(/N)=N\O)=O Chemical compound COC(c(cc1)cc([N+]([O-])=O)c1/C(/N)=N\O)=O PJAUWJBJFGOLTN-UHFFFAOYSA-N 0.000 description 1
- IGHWNCLZGNNKBN-UHFFFAOYSA-N COC(c(cc1)ccc1/C(/N)=N/O)=O Chemical compound COC(c(cc1)ccc1/C(/N)=N/O)=O IGHWNCLZGNNKBN-UHFFFAOYSA-N 0.000 description 1
- PSZYWMHNXWCCLS-UHFFFAOYSA-N COC(c(cc1[N+]([O-])=O)ccc1C#N)=O Chemical compound COC(c(cc1[N+]([O-])=O)ccc1C#N)=O PSZYWMHNXWCCLS-UHFFFAOYSA-N 0.000 description 1
- PDOPWXBXJAMQLL-UHFFFAOYSA-N Cc(cc(c(C)c1)Cl)c1OC Chemical compound Cc(cc(c(C)c1)Cl)c1OC PDOPWXBXJAMQLL-UHFFFAOYSA-N 0.000 description 1
- MCRDIULWYOXUKX-UHFFFAOYSA-N Cc(cc(c(C)c1)F)c1OC Chemical compound Cc(cc(c(C)c1)F)c1OC MCRDIULWYOXUKX-UHFFFAOYSA-N 0.000 description 1
- CYEXEOXALMJXDI-UHFFFAOYSA-N Cc(cc(cc1)Br)c1C(OC)=O Chemical compound Cc(cc(cc1)Br)c1C(OC)=O CYEXEOXALMJXDI-UHFFFAOYSA-N 0.000 description 1
- WCZWEODOIUKVHX-UHFFFAOYSA-N Cc(cc1C(F)(F)F)ccc1C#N Chemical compound Cc(cc1C(F)(F)F)ccc1C#N WCZWEODOIUKVHX-UHFFFAOYSA-N 0.000 description 1
- WRAFGENAJWPJMA-UHFFFAOYSA-N Cc1c(cc(-c2n[o]c(-c3ccc(C(O)=C)c(C)c3)n2)[o]2)c2c(C)cc1 Chemical compound Cc1c(cc(-c2n[o]c(-c3ccc(C(O)=C)c(C)c3)n2)[o]2)c2c(C)cc1 WRAFGENAJWPJMA-UHFFFAOYSA-N 0.000 description 1
- BBSGLOXGWJXZPN-UHFFFAOYSA-N Cc1c(cc(-c2n[s]c(-c3ccc(C(O)=O)c(F)c3)n2)[o]2)c2c(C)cc1 Chemical compound Cc1c(cc(-c2n[s]c(-c3ccc(C(O)=O)c(F)c3)n2)[o]2)c2c(C)cc1 BBSGLOXGWJXZPN-UHFFFAOYSA-N 0.000 description 1
- JSGOXXPITLWUSW-UHFFFAOYSA-N Cc1c(cc(-c2nc(-c(c([N+]([O-])=O)c3)ccc3C(OC)=O)n[o]2)[o]2)c2c(C)cc1 Chemical compound Cc1c(cc(-c2nc(-c(c([N+]([O-])=O)c3)ccc3C(OC)=O)n[o]2)[o]2)c2c(C)cc1 JSGOXXPITLWUSW-UHFFFAOYSA-N 0.000 description 1
- WGPGONBALWALNL-UHFFFAOYSA-N Cc1c(cc(-c2nc(-c3ccc(C(O)=O)c(F)c3)n[o]2)[o]2)c2c(C)cc1 Chemical compound Cc1c(cc(-c2nc(-c3ccc(C(O)=O)c(F)c3)n[o]2)[o]2)c2c(C)cc1 WGPGONBALWALNL-UHFFFAOYSA-N 0.000 description 1
- CLSYIZNEJIOADT-UHFFFAOYSA-N Cc1c(cc(C(O)=O)[s]2)c2c(C)cc1 Chemical compound Cc1c(cc(C(O)=O)[s]2)c2c(C)cc1 CLSYIZNEJIOADT-UHFFFAOYSA-N 0.000 description 1
- XBBTUIGZSDDAHJ-UHFFFAOYSA-N Cc1c2nc(-c3nc(-c4ccc(C(OC)=C)c(F)c4)n[o]3)[o]c2c(C)cc1 Chemical compound Cc1c2nc(-c3nc(-c4ccc(C(OC)=C)c(F)c4)n[o]3)[o]c2c(C)cc1 XBBTUIGZSDDAHJ-UHFFFAOYSA-N 0.000 description 1
- HDWQTTFZIOYIEM-UHFFFAOYSA-N Cc1cc(Cl)c(C)c2c1[o]c(-c1nc(-c(cc3)ccc3C(O)=O)n[o]1)c2 Chemical compound Cc1cc(Cl)c(C)c2c1[o]c(-c1nc(-c(cc3)ccc3C(O)=O)n[o]1)c2 HDWQTTFZIOYIEM-UHFFFAOYSA-N 0.000 description 1
- QHQCPKPQLWGMQW-UHFFFAOYSA-N Cc1cc(O)c(C)cc1C(F)(F)F Chemical compound Cc1cc(O)c(C)cc1C(F)(F)F QHQCPKPQLWGMQW-UHFFFAOYSA-N 0.000 description 1
- UIYLRYDAIPKNTC-UHFFFAOYSA-N Cc1cc(OC)c(C)cc1C(F)(F)F Chemical compound Cc1cc(OC)c(C)cc1C(F)(F)F UIYLRYDAIPKNTC-UHFFFAOYSA-N 0.000 description 1
- NHAUBUMQRJWWAT-UHFFFAOYSA-N Cc1ccc(C)c(S)c1 Chemical compound Cc1ccc(C)c(S)c1 NHAUBUMQRJWWAT-UHFFFAOYSA-N 0.000 description 1
- UIVIQQZTCSJUJJ-UHFFFAOYSA-N Cc1ccc(C)c2c1cc(-c1n[o]c(-c3ccc(C(O)=O)c(F)c3)n1)[o]2 Chemical compound Cc1ccc(C)c2c1cc(-c1n[o]c(-c3ccc(C(O)=O)c(F)c3)n1)[o]2 UIVIQQZTCSJUJJ-UHFFFAOYSA-N 0.000 description 1
- NHERYJFCKTVTTE-UHFFFAOYSA-N Cc1ccc(C)c2c1cc(-c1nc(-c(c(N)c3)ccc3C(OC)=C)n[o]1)[o]2 Chemical compound Cc1ccc(C)c2c1cc(-c1nc(-c(c(N)c3)ccc3C(OC)=C)n[o]1)[o]2 NHERYJFCKTVTTE-UHFFFAOYSA-N 0.000 description 1
- FRZGIDLPTLULST-UHFFFAOYSA-N Cc1ccc(C)c2c1cc(-c1nnc(-c(ccc(C(O)=O)c3)c3Cl)[o]1)[o]2 Chemical compound Cc1ccc(C)c2c1cc(-c1nnc(-c(ccc(C(O)=O)c3)c3Cl)[o]1)[o]2 FRZGIDLPTLULST-UHFFFAOYSA-N 0.000 description 1
- SGVOVLXBICCLPF-UHFFFAOYSA-N Cc1ccc(C)c2c1cc(/C(/N)=N/O)[o]2 Chemical compound Cc1ccc(C)c2c1cc(/C(/N)=N/O)[o]2 SGVOVLXBICCLPF-UHFFFAOYSA-N 0.000 description 1
- YFOWRHSVKUBSHX-UHFFFAOYSA-N Cc1ccc(C)c2c1nc(-c1nc(-c3ccc(C(O)=C)c(F)c3)n[o]1)[o]2 Chemical compound Cc1ccc(C)c2c1nc(-c1nc(-c3ccc(C(O)=C)c(F)c3)n[o]1)[o]2 YFOWRHSVKUBSHX-UHFFFAOYSA-N 0.000 description 1
- ZQROAOQEUKHZRF-UHFFFAOYSA-N Clc(c1c2[o]cc1)ccc2Cl Chemical compound Clc(c1c2[o]cc1)ccc2Cl ZQROAOQEUKHZRF-UHFFFAOYSA-N 0.000 description 1
- CXUWGEWQRCXJDC-UHFFFAOYSA-N Clc1nc(Br)n[s]1 Chemical compound Clc1nc(Br)n[s]1 CXUWGEWQRCXJDC-UHFFFAOYSA-N 0.000 description 1
- MLKHYEZBRDXLEK-UHFFFAOYSA-N N#Cc(c(C(F)(F)F)c1)ccc1C(O)=O Chemical compound N#Cc(c(C(F)(F)F)c1)ccc1C(O)=O MLKHYEZBRDXLEK-UHFFFAOYSA-N 0.000 description 1
- HSGBFBIYVJAWNJ-UHFFFAOYSA-N OC(c(cc1)cc(Cl)c1-c1n[o]c(-c2cc(c(C(F)(F)F)ccc3F)c3[o]2)n1)=O Chemical compound OC(c(cc1)cc(Cl)c1-c1n[o]c(-c2cc(c(C(F)(F)F)ccc3F)c3[o]2)n1)=O HSGBFBIYVJAWNJ-UHFFFAOYSA-N 0.000 description 1
- BHJTWEVVAVQXJM-UHFFFAOYSA-N OC(c(cc1)ccc1-c1n[o]c(-c([o]c2c(cc3)Cl)cc2c3Cl)n1)=O Chemical compound OC(c(cc1)ccc1-c1n[o]c(-c([o]c2c(cc3)Cl)cc2c3Cl)n1)=O BHJTWEVVAVQXJM-UHFFFAOYSA-N 0.000 description 1
- GLMFDNLYMXMPNA-UHFFFAOYSA-N OC(c1cc(c(Cl)ccc2Cl)c2[o]1)=O Chemical compound OC(c1cc(c(Cl)ccc2Cl)c2[o]1)=O GLMFDNLYMXMPNA-UHFFFAOYSA-N 0.000 description 1
- RANCECPPZPIPNO-UHFFFAOYSA-N Oc1cc(Cl)ccc1Cl Chemical compound Oc1cc(Cl)ccc1Cl RANCECPPZPIPNO-UHFFFAOYSA-N 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N c1nc2ccccc2[s]1 Chemical compound c1nc2ccccc2[s]1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422472 | 2014-12-17 | ||
| GB1422472.9 | 2014-12-17 | ||
| PCT/EP2015/080029 WO2016097004A1 (en) | 2014-12-17 | 2015-12-16 | BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015367531A1 AU2015367531A1 (en) | 2017-07-06 |
| AU2015367531B2 true AU2015367531B2 (en) | 2020-04-30 |
Family
ID=55027725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015367531A Active AU2015367531B2 (en) | 2014-12-17 | 2015-12-16 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARbeta) agonists |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9994559B2 (https=) |
| EP (1) | EP3233842B1 (https=) |
| JP (1) | JP6596090B2 (https=) |
| KR (1) | KR102526625B1 (https=) |
| CN (1) | CN107207488B (https=) |
| AU (1) | AU2015367531B2 (https=) |
| BR (1) | BR112017012588B8 (https=) |
| CA (1) | CA2970574C (https=) |
| ES (1) | ES3029609T3 (https=) |
| IL (1) | IL252882B (https=) |
| WO (1) | WO2016097004A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107207488B (zh) | 2014-12-17 | 2020-11-17 | 伦敦皇家学院 | 作为视黄酸受体β(RARβ)激动剂的双环杂芳基-杂芳基-苯甲酸化合物 |
| GB201610867D0 (en) * | 2016-06-22 | 2016-08-03 | King S College London | Crystalline forms of a therapeutic compound and processes for their preparation |
| CN111892591A (zh) * | 2019-05-06 | 2020-11-06 | 南京科技职业学院 | 一种维奈托克关键中间体的合成方法 |
| GB201907647D0 (en) * | 2019-05-30 | 2019-07-17 | King S College London | Therapeutic methods |
| CN115427401B (zh) | 2020-05-29 | 2025-04-11 | 巴斯夫欧洲公司 | 取代4-(n′-羟基甲脒基)苯甲酸的制备 |
| CN112552252B (zh) * | 2020-09-30 | 2024-01-02 | 浙江美诺华药物化学有限公司 | 一种氟雷拉纳中间体的制备方法 |
| CN113264832A (zh) * | 2021-05-13 | 2021-08-17 | 南京爱可德夫科技开发有限公司 | 一种合成高纯度2-氟-4-溴苯甲酸叔丁酯的方法 |
| CN116640071B (zh) * | 2023-05-04 | 2024-08-30 | 四川青木制药有限公司 | 一种制备2-甲基4-甲醛肟基苯甲酸及其酯类衍生物的方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110959A (en) * | 1996-03-18 | 2000-08-29 | Eisai Co., Ltd. | Carboxylic acid derivatives having fused rings |
| US6355669B1 (en) * | 1997-10-22 | 2002-03-12 | Eisai Co., Ltd. | Retinoic acid agonists as preventive and therapeutic agents for nephritis |
| WO2003062230A1 (en) * | 2002-01-21 | 2003-07-31 | Eisai Co., Ltd. | Conbinatorial library of heterocycle compounds |
| US6992096B2 (en) * | 2003-04-11 | 2006-01-31 | Ptc Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| US20090253699A1 (en) * | 2004-10-13 | 2009-10-08 | Pct Therapeutics, Inc. | Compounds for Nonsense Suppression, and Methods for Their Use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP9802290A3 (en) | 1995-06-07 | 2002-02-28 | Nippon Shinyaku Co Ltd | Pyrrole derivatives and pharmaceutical compositions containing them |
| JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| JPH10158192A (ja) | 1996-10-03 | 1998-06-16 | Eisai Co Ltd | 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物 |
| GB9907461D0 (en) | 1999-03-31 | 1999-05-26 | King S College London | Neurite regeneration |
| JP2000154150A (ja) * | 1997-10-22 | 2000-06-06 | Eisai Co Ltd | 腎炎予防・治療剤としてのレチノイン酸アゴニスト |
| US6809107B1 (en) * | 1999-07-09 | 2004-10-26 | Ortho-Mcneil Pharmaceutical, Inc. | Neurotrophic pyrrolidines and piperidines, and related compositions and methods |
| US20020048580A1 (en) * | 2000-06-07 | 2002-04-25 | Institut National De La Sante Et De La Recherche Medicale | Method of inducing lung branching |
| KR20040004705A (ko) | 2001-06-08 | 2004-01-13 | 시토비아 인크. | 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도 |
| JP2003081832A (ja) | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
| IL166510A0 (en) | 2002-08-09 | 2006-01-15 | Nps Pharma Inc | 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5 |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| US20090176837A1 (en) | 2005-07-12 | 2009-07-09 | Sony Corporation | Compounds with activity at retinoic acid receptors |
| CN102047061A (zh) | 2008-05-30 | 2011-05-04 | 福斯特韦勒能源股份公司 | 通过氧化燃料燃烧发电的方法和系统 |
| KR101220182B1 (ko) * | 2009-02-25 | 2013-01-11 | 에스케이바이오팜 주식회사 | 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법 |
| GB0915196D0 (en) * | 2009-09-01 | 2009-10-07 | King S College London | Therapeutic compounds and their use |
| US20120289476A1 (en) | 2009-12-11 | 2012-11-15 | Jay Allan Barth | Methods for treating methylmalonic acidemia |
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CN107207488B (zh) * | 2014-12-17 | 2020-11-17 | 伦敦皇家学院 | 作为视黄酸受体β(RARβ)激动剂的双环杂芳基-杂芳基-苯甲酸化合物 |
-
2015
- 2015-12-16 CN CN201580073462.9A patent/CN107207488B/zh active Active
- 2015-12-16 EP EP15817206.4A patent/EP3233842B1/en active Active
- 2015-12-16 AU AU2015367531A patent/AU2015367531B2/en active Active
- 2015-12-16 WO PCT/EP2015/080029 patent/WO2016097004A1/en not_active Ceased
- 2015-12-16 KR KR1020177019558A patent/KR102526625B1/ko active Active
- 2015-12-16 CA CA2970574A patent/CA2970574C/en active Active
- 2015-12-16 BR BR112017012588A patent/BR112017012588B8/pt active IP Right Grant
- 2015-12-16 US US15/533,492 patent/US9994559B2/en active Active
- 2015-12-16 JP JP2017532660A patent/JP6596090B2/ja active Active
- 2015-12-16 ES ES15817206T patent/ES3029609T3/es active Active
-
2017
- 2017-06-13 IL IL252882A patent/IL252882B/en active IP Right Grant
-
2018
- 2018-06-05 US US15/997,796 patent/US10385044B2/en active Active
-
2019
- 2019-08-09 US US16/536,441 patent/US10752616B2/en active Active
-
2020
- 2020-08-19 US US16/997,855 patent/US11401265B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110959A (en) * | 1996-03-18 | 2000-08-29 | Eisai Co., Ltd. | Carboxylic acid derivatives having fused rings |
| US6355669B1 (en) * | 1997-10-22 | 2002-03-12 | Eisai Co., Ltd. | Retinoic acid agonists as preventive and therapeutic agents for nephritis |
| WO2003062230A1 (en) * | 2002-01-21 | 2003-07-31 | Eisai Co., Ltd. | Conbinatorial library of heterocycle compounds |
| US6992096B2 (en) * | 2003-04-11 | 2006-01-31 | Ptc Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| US20090253699A1 (en) * | 2004-10-13 | 2009-10-08 | Pct Therapeutics, Inc. | Compounds for Nonsense Suppression, and Methods for Their Use |
Also Published As
| Publication number | Publication date |
|---|---|
| US10385044B2 (en) | 2019-08-20 |
| CA2970574A1 (en) | 2016-06-23 |
| US20210130337A1 (en) | 2021-05-06 |
| EP3233842B1 (en) | 2025-03-26 |
| IL252882B (en) | 2020-04-30 |
| US20200131165A1 (en) | 2020-04-30 |
| US9994559B2 (en) | 2018-06-12 |
| WO2016097004A1 (en) | 2016-06-23 |
| EP3233842C0 (en) | 2025-03-26 |
| US20170327489A1 (en) | 2017-11-16 |
| BR112017012588B1 (pt) | 2023-11-07 |
| IL252882A0 (en) | 2017-08-31 |
| KR102526625B1 (ko) | 2023-04-27 |
| EP3233842A1 (en) | 2017-10-25 |
| KR20170097125A (ko) | 2017-08-25 |
| CN107207488B (zh) | 2020-11-17 |
| JP2017537967A (ja) | 2017-12-21 |
| AU2015367531A1 (en) | 2017-07-06 |
| US20190010146A1 (en) | 2019-01-10 |
| BR112017012588B8 (pt) | 2024-02-15 |
| US10752616B2 (en) | 2020-08-25 |
| BR112017012588A2 (pt) | 2018-11-13 |
| JP6596090B2 (ja) | 2019-10-23 |
| US11401265B2 (en) | 2022-08-02 |
| CA2970574C (en) | 2023-09-19 |
| CN107207488A (zh) | 2017-09-26 |
| ES3029609T3 (en) | 2025-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015367531B2 (en) | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARbeta) agonists | |
| US10676438B2 (en) | KCNQ2-5 channel activator | |
| US12428379B2 (en) | Acylsulfonamide KAT6A inhibitors | |
| JP7033588B2 (ja) | 癌の治療に有用なｐａｒｐ１、ｐａｒｐ２、および／またはチューブリンの阻害剤としてのフタラジン誘導体 | |
| CA3058533A1 (en) | Compounds useful as inhibitors of alcat 1 | |
| US11584741B2 (en) | Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation | |
| MX2014002968A (es) | 4,5,6,7 - tetrahidro - 1h - pirazolo [4,3 -c] piridinas sustituidas con indanilo, su uso como medicamento, y preparaciones farmaceuticas que las comprenden. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |